HRP20200370T1 - Biokemijski stabilizirano hiv-1 trimer cjepivo - Google Patents

Biokemijski stabilizirano hiv-1 trimer cjepivo Download PDF

Info

Publication number
HRP20200370T1
HRP20200370T1 HRP20200370TT HRP20200370T HRP20200370T1 HR P20200370 T1 HRP20200370 T1 HR P20200370T1 HR P20200370T T HRP20200370T T HR P20200370TT HR P20200370 T HRP20200370 T HR P20200370T HR P20200370 T1 HRP20200370 T1 HR P20200370T1
Authority
HR
Croatia
Prior art keywords
hiv
trimer
asn
thr
vaccine
Prior art date
Application number
HRP20200370TT
Other languages
English (en)
Inventor
Stephen C. Harrison
Bing Chen
Dan H. Barouch
Joseph P. Nikolola
Michael Scott Seaman
Original Assignee
Children's Medical Center Corporation
Beth Israel Deaconess Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc. filed Critical Children's Medical Center Corporation
Publication of HRP20200370T1 publication Critical patent/HRP20200370T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. HIV gp140 trimer koji obuhvaća HIV gp140 polipeptid koji sadrži sekvencu aminokiselina najmanje 95% identično sekvenci: [image] [image] sadrži trimerizacijsku domenu, i peptid promjenjive petlje V3; gdje HIV gp140 trimer trimer može izazvati proizvodnju neutralizacijskih antiseruma protiv HIV - a kada se stabilizirani trimer daje subjektu.
2. HIV gp140 trimer, sukladno patentnom zahtjevu 1, koji sadrži peptid promjenjive petlje V3 koji se sastoji od sekvence Thr Arg Pro Asn Asn Thn Arg Lys Ser Met Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Gly Asp Ile Arg Gln Ala Tyr (SEQ ID N0: 8);
3. HIV gp 140 trimer sukladno zahtjevima 1 ili 2, gdje je trimerizacijska domena T4-fibritin fold trimerizacijska domena.
4. HIV gp 140 trimer, sukladno bilo kojem od prethodno navedenih zahtjeva 1 do 3, gdje HIV gp140 polipeptid uključujuje promjenjive petlje peptida V1 i V2, navedena V1 petlja peptid sastavljena od sekvenci Thr Asn Ala Thr Phe Lys Asn Asn Val Thr Asn Asp Met Asn Lys Glu Ile Arg Asn Cys Ser Phe Asn Thr Thr Thr Glu Ile Arg (SEQ ID NO: 4); i navedena V2 petlja peptid sastavljena od sekvenci Ser Phe Asn Thr Thr Thr Glu Ile Arg Asp Lys Gln Gln Gly Tyr Ala Leu Phe Tyr Arg Pro Asp Ile Val Leu Leu Lys Glu Asn Arg Asn Asn Ser Asn Asn Ser Glu Tyr Ile Leu Ile Asn (SEQ ID NO: 6).
5. HIV gp 140 trimer, sukladno bilo kojem od prethodno navedenih zahtjeva 1 do 4, gdje HIV gp140 polipeptid obuhvaća sekvencu aminokiselina [image] [image]
6. HIV gp 140 trimer, sukladno bilo kojem od prethodno navedenih zahtjeva 1 do 5, gdje HIV je HIV-1
7. HIV gp 140 trimer sukladno zahtjevim 1 – 6, gdje neutralizirajući anti-HIV antiserum neutralizira HIV-1, odabranu izmedju jednog ili više Clade A, Clade B ili Clade C.
8. Farmaceutski spoj sadrži HIV gp 140 trimer, kao što je naznačenu u zahtjevima 1 - 7.
9. HIV gp 140 trimer, sukladno zahtjevima 1 – 7, ili farmaceutski spoj, sukladno zahtjevu 8. za korištenje kao cjepiva.
10. Cjepivo sadrži HIV gp 140 trimer sukladno patentnim zahtjevima 1 – 7.
11. Cjepivo sadrži sekvence nukleinske kiseline koja kodira HIV gp 140 trimer sukladno zahtjevima 1 – 7.
12. HIV gp 140 trimer sukladno patentnim zahtjevima 1 – 7 ili farmaceutski spoj sukladno patentnom zahtjevu 8, ili cjepivo sukladno patentnim zahtjevima 10 ili 11, naznačeni time, što se koristi kao postupak za proizvodnju neutralizirajućih seruma protiv HIV-a nakon injektiranja u subjekta.
13. HIV gp 140 trimer, sukladno patentnim zahtjevima 1- 7, ili farmaceuski spoj sukladno zahtjevu 8, ili cjepivo sukladno patentnim zahtjevima 10 ili 11, za uporabu za imunizaciju subjekta protiv HIV-a.
14. Postupak dobivanja HIV gp 140 trimera sukladno bilo kojem od zahtjeva 1 – 7, gdje postupak uključuje ekspresiju u eukariotskoj stanici domaćina vektora koji sadrži polipeptid i sadrži nukleinsku kiselinu koja enkodira sekvencu odgovarajućeg HIV gp 140 polipeptida.
15. Postupak dobivanja farmaceutskog spoja ili cjepiva koje sadrže HIV gp 140 trimer, spomenuti postupak sadrži postupak proizvodnje spomenutog HIV gp 140 trimera sukladno patentnom zahtjevu 14, i uključuje dobiveni HIV gp 140 trimer u farmaceutski spoj ili cjepivo sastavljeno od farmacutski prihvatljivog nossča.
HRP20200370TT 2008-10-10 2020-03-04 Biokemijski stabilizirano hiv-1 trimer cjepivo HRP20200370T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10444908P 2008-10-10 2008-10-10
EP18150843.3A EP3335728B8 (en) 2008-10-10 2009-10-13 Biochemically stabilized hiv-1 env trimer vaccine

Publications (1)

Publication Number Publication Date
HRP20200370T1 true HRP20200370T1 (hr) 2020-06-12

Family

ID=42101262

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20180281TT HRP20180281T1 (hr) 2008-10-10 2018-02-15 Biokemijski stabilizirano hiv-1 env trimer cjepivo
HRP20200370TT HRP20200370T1 (hr) 2008-10-10 2020-03-04 Biokemijski stabilizirano hiv-1 trimer cjepivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20180281TT HRP20180281T1 (hr) 2008-10-10 2018-02-15 Biokemijski stabilizirano hiv-1 env trimer cjepivo

Country Status (14)

Country Link
US (6) US9707289B2 (hr)
EP (2) EP3335728B8 (hr)
AU (1) AU2009303284B2 (hr)
CY (2) CY1119921T1 (hr)
DK (2) DK3335728T3 (hr)
ES (2) ES2765890T3 (hr)
HR (2) HRP20180281T1 (hr)
HU (2) HUE037270T2 (hr)
LT (2) LT2340038T (hr)
PL (2) PL2340038T3 (hr)
PT (2) PT2340038T (hr)
SI (2) SI2340038T1 (hr)
TR (1) TR201802130T4 (hr)
WO (1) WO2010042942A2 (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
LT2340038T (lt) 2008-10-10 2018-04-10 Children`S Medical Center Corporation Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
CA2757240A1 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
US9060984B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
US20130302366A1 (en) * 2012-05-09 2013-11-14 Christopher Marshall Conformationally Specific Viral Immunogens
US11149069B2 (en) 2012-08-03 2021-10-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
AP2015008634A0 (en) * 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
WO2014134547A1 (en) 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
US9675687B2 (en) 2013-03-15 2017-06-13 University Of Massachusetts Compositions and methods to treat AIDS
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
WO2015051270A1 (en) 2013-10-04 2015-04-09 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
JP6510149B2 (ja) 2015-12-15 2019-05-08 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法
BR112018075785A2 (pt) 2016-06-16 2019-04-02 Janssen Vaccines & Prevention B.V. formulação de vacina para o hiv
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
IL294832A (en) 2016-09-15 2022-09-01 Janssen Vaccines Prevention B V HIV envelope proteins with trimer-stabilizing mutations
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2018229711A1 (en) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
CA3069052A1 (en) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11517618B2 (en) 2018-09-25 2022-12-06 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR20220092896A (ko) 2019-11-07 2022-07-04 얀센 백신스 앤드 프리벤션 비.브이. 단백질 정제
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ. 小型タンパク質
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
AU2003298912B2 (en) * 2002-12-03 2011-06-02 Advanced Bioscience Laboratories, Inc. Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
US20080274134A1 (en) * 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
ATE527281T1 (de) * 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
US20100221241A1 (en) * 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007149491A2 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
LT2340038T (lt) 2008-10-10 2018-04-10 Children`S Medical Center Corporation Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
DK2358757T3 (da) 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
AP2015008634A0 (en) * 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
EP3019518B1 (en) * 2013-07-08 2019-04-03 Novartis AG Rotavirus particles with chimeric surface proteins
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10444908B2 (en) 2016-12-31 2019-10-15 Innoventions, Inc. Virtual touchpads for wearable and portable devices

Also Published As

Publication number Publication date
AU2009303284A1 (en) 2010-04-15
PL3335728T3 (pl) 2020-06-29
EP3335728A1 (en) 2018-06-20
US20120045472A1 (en) 2012-02-23
EP2340038A4 (en) 2012-08-15
WO2010042942A2 (en) 2010-04-15
ES2765890T3 (es) 2020-06-11
US20200323976A1 (en) 2020-10-15
EP2340038B1 (en) 2018-01-10
TR201802130T4 (tr) 2018-03-21
CY1122745T1 (el) 2021-01-27
PL2340038T3 (pl) 2018-07-31
WO2010042942A3 (en) 2010-06-24
US20180207259A1 (en) 2018-07-26
US11229696B2 (en) 2022-01-25
US10307478B2 (en) 2019-06-04
CY1119921T1 (el) 2018-12-12
PT2340038T (pt) 2018-02-21
DK3335728T3 (da) 2020-02-24
US20190240319A1 (en) 2019-08-08
US9950060B2 (en) 2018-04-24
DK2340038T3 (en) 2018-02-26
LT3335728T (lt) 2020-03-10
SI3335728T1 (sl) 2020-04-30
LT2340038T (lt) 2018-04-10
HUE049393T2 (hu) 2020-09-28
PT3335728T (pt) 2020-02-19
US9707289B2 (en) 2017-07-18
EP3335728B1 (en) 2019-12-25
ES2659875T3 (es) 2018-03-19
HUE037270T2 (hu) 2018-08-28
HRP20180281T1 (hr) 2018-05-04
US10463729B2 (en) 2019-11-05
EP3335728B8 (en) 2020-03-11
US10653770B2 (en) 2020-05-19
US20170290907A1 (en) 2017-10-12
EP2340038A2 (en) 2011-07-06
SI2340038T1 (en) 2018-05-31
AU2009303284B2 (en) 2016-01-28
US20200023056A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
HRP20200370T1 (hr) Biokemijski stabilizirano hiv-1 trimer cjepivo
KR102638978B1 (ko) Rsv에 대한 백신
CN107022008B (zh) 广谱地抑制人类冠状病毒感染的多肽及其应用
IL278014B1 (en) Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use
HRP20140109T1 (hr) Novi imunoadjuvantni spojevi na bazi flagelina i njihova upotreba
EA035909B1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
McGaughey et al. Progress towards the development of a HIV-1 gp41-directed vaccine
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
CA3025441A1 (en) Stabilized pre-fusion rsv f proteins
KR20150023735A (ko) 안정화된 gp120
WO2017207477A1 (en) Stabilized pre-fusion rsv f proteins
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
CN113227123A (zh) 重组呼吸道合胞病毒f蛋白以及包含该蛋白的疫苗组合物
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
EP1615610A2 (en) Inhibitors of coronavirus
CN117126292A (zh) 痘病毒重组嵌合抗原、包含其的免疫原性组合物及其应用
WO2012050893A3 (en) Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein
EA201190097A1 (ru) РАСЩЕПЛЕНИЕ gp41
Crane et al. Identification of the fusion domain in the visna virus transmembrane protein
AU2015226580B2 (en) Beta-hairpin peptides having anti-viral properties against the dengue virus
CN101838318B (zh) 抗hiv-i的多肽、其编码序列及其用途
Shcherbakova et al. Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12
RU2020122924A (ru) Пептидные иммуногены il-31 и их составы для лечения и/или профилактики атопического дерматита
WO2013140169A1 (en) Immunogenic composition and methods of use thereof
RU2021100733A (ru) Неоантигены и их применение